- Home
- CLDI vs BGLC Comparison
CLDI vs BGLC Comparison
Compare CLDI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- BGLC
- Stock Information
- Founded
- CLDI 2014
- BGLC 2017
- Country
- CLDI United States
- BGLC Malaysia
- Employees
- CLDI N/A
- BGLC N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- BGLC Medical Specialities
- Sector
- CLDI Health Care
- BGLC Health Care
- Exchange
- CLDI Nasdaq
- BGLC Nasdaq
- Market Cap
- CLDI 8.7M
- BGLC 10.4M
- IPO Year
- CLDI N/A
- BGLC N/A
- Fundamental
- Price
- CLDI $1.58
- BGLC $5.06
- Analyst Decision
- CLDI
- BGLC
- Analyst Count
- CLDI 0
- BGLC 0
- Target Price
- CLDI N/A
- BGLC N/A
- AVG Volume (30 Days)
- CLDI 161.6K
- BGLC 36.8K
- Earning Date
- CLDI 11-11-2025
- BGLC 11-14-2025
- Dividend Yield
- CLDI N/A
- BGLC N/A
- EPS Growth
- CLDI N/A
- BGLC N/A
- EPS
- CLDI N/A
- BGLC N/A
- Revenue
- CLDI N/A
- BGLC $9,551,559.00
- Revenue This Year
- CLDI N/A
- BGLC N/A
- Revenue Next Year
- CLDI N/A
- BGLC N/A
- P/E Ratio
- CLDI N/A
- BGLC N/A
- Revenue Growth
- CLDI N/A
- BGLC 4.01
- 52 Week Low
- CLDI $1.41
- BGLC $2.01
- 52 Week High
- CLDI $46.68
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- CLDI 44.14
- BGLC 45.78
- Support Level
- CLDI $1.51
- BGLC $5.04
- Resistance Level
- CLDI $1.74
- BGLC $5.26
- Average True Range (ATR)
- CLDI 0.10
- BGLC 0.27
- MACD
- CLDI 0.04
- BGLC -0.04
- Stochastic Oscillator
- CLDI 30.43
- BGLC 22.03
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.